CO2022008813A2 - Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp - Google Patents

Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp

Info

Publication number
CO2022008813A2
CO2022008813A2 CONC2022/0008813A CO2022008813A CO2022008813A2 CO 2022008813 A2 CO2022008813 A2 CO 2022008813A2 CO 2022008813 A CO2022008813 A CO 2022008813A CO 2022008813 A2 CO2022008813 A2 CO 2022008813A2
Authority
CO
Colombia
Prior art keywords
tslp
variable domains
polypeptides
target
immunoglobulin variable
Prior art date
Application number
CONC2022/0008813A
Other languages
English (en)
Spanish (es)
Inventor
Heidi Rommelaere
Ann Brigé
Sigrid Cornelis
Eric Lorent
Bruno Dombrecht
Melanie Rieger
Timothy Soos
John Park
Bernd Weigle
Klaus Erb
Original Assignee
Sanofi Sa
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Ablynx Nv filed Critical Sanofi Sa
Publication of CO2022008813A2 publication Critical patent/CO2022008813A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CONC2022/0008813A 2019-12-09 2022-06-24 Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp CO2022008813A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945391P 2019-12-09 2019-12-09
EP20305064 2020-01-27
PCT/EP2020/085304 WO2021116182A1 (en) 2019-12-09 2020-12-09 Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp

Publications (1)

Publication Number Publication Date
CO2022008813A2 true CO2022008813A2 (es) 2022-07-19

Family

ID=73793214

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0008813A CO2022008813A2 (es) 2019-12-09 2022-06-24 Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp

Country Status (14)

Country Link
US (5) US20210188965A1 (cg-RX-API-DMAC7.html)
EP (1) EP4072674A1 (cg-RX-API-DMAC7.html)
JP (2) JP7641968B2 (cg-RX-API-DMAC7.html)
KR (1) KR102984686B1 (cg-RX-API-DMAC7.html)
CN (1) CN114980974A (cg-RX-API-DMAC7.html)
AU (1) AU2020400938A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022010223A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163910A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022008813A2 (cg-RX-API-DMAC7.html)
IL (1) IL293548A (cg-RX-API-DMAC7.html)
MX (1) MX2022007035A (cg-RX-API-DMAC7.html)
MY (1) MY208649A (cg-RX-API-DMAC7.html)
TW (2) TWI861302B (cg-RX-API-DMAC7.html)
WO (1) WO2021116182A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
CN114980974A (zh) 2019-12-09 2022-08-30 艾伯霖克斯公司 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽
WO2022063984A1 (en) * 2020-09-25 2022-03-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
CA3217029A1 (en) * 2021-05-30 2022-12-08 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
KR20250025381A (ko) 2022-06-17 2025-02-21 아포지 바이오로직스, 인크. 인터류킨 13에 결합하는 항체 및 사용 방법
WO2024017915A1 (en) * 2022-07-18 2024-01-25 Ablynx N.V. Cx3cr1-binding compounds, uses thereof and related methods
CN118005784A (zh) 2022-11-08 2024-05-10 上海洛启生物医药技术有限公司 抗il-13长效纳米抗体序列及其应用
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
AU2024247861A1 (en) 2023-03-24 2025-11-06 Sanofi Asthma treatment by blocking il-13 and tslp
EP4435005A1 (en) 2023-03-24 2024-09-25 Sanofi Asthma treatment by blocking il-13 and tslp
EP4731663A2 (en) * 2023-06-22 2026-04-29 Paragon Therapeutics, Inc. Antibodies that bind interleukin 13 and tslp or tslpr and methods of use
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
AR134101A1 (es) * 2023-10-12 2025-12-03 Innovent Biologics Suzhou Co Ltd Anticuerpos anti-tslp y usos de los mismos
WO2025209486A1 (en) * 2024-04-02 2025-10-09 Keymed Biosciences (Chengdu) Co., Ltd. Antibodies targeting il-13 and tslp and uses thereof
WO2026041740A1 (en) 2024-08-21 2026-02-26 Sanofi Treatment of high-risk asthma by blocking il-13 and tslp
WO2026055143A2 (en) * 2024-09-03 2026-03-12 Attovia Therapeutics, Inc. Il13-binding polypeptides and uses thereof
WO2026067440A1 (zh) * 2024-09-29 2026-04-02 四川科伦博泰生物医药股份有限公司 Tslp/il-13双特异性抗体及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
AU2007237501A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. DP-78-like nanobodies
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン.ヴェー. Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US20100113339A1 (en) * 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
AR064333A1 (es) * 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
CA2744588A1 (en) * 2008-11-26 2010-06-03 Glaxo Group Limited Ligands that bind il-13
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
LT3466972T (lt) 2011-06-23 2026-06-25 Ablynx Nv Serumo albuminą surišantys baltymai
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
CN107428828A (zh) * 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 Tslp结合蛋白
HUE057241T2 (hu) 2015-11-13 2022-04-28 Ablynx Nv Javított, szérumalbumint kötõ immunoglobulin variábilis domének
US10544222B2 (en) * 2015-11-18 2020-01-28 Merck Sharp & Dohme Corp. PD1/CTLA4 binders
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
CA3006398A1 (en) * 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
US11248057B2 (en) * 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
US11840569B2 (en) 2016-11-16 2023-12-12 Ablynx N.V. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
WO2018104444A1 (en) 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
EP4442709A3 (en) 2017-01-17 2024-12-25 Ablynx NV Improved serum albumin binders
KR20260100427A (ko) * 2018-03-28 2026-06-29 오리오니스 바이오사이언시즈 인코포레이티드 이작용성 단백질 및 이의 작제물
CN112687354B (zh) * 2019-01-29 2022-07-12 杭州纽安津生物科技有限公司 针对靶向药物PI3K、AKT、mTOR通路的激酶抑制剂的多肽疫苗组合及其设计方法
CN114980974A (zh) 2019-12-09 2022-08-30 艾伯霖克斯公司 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp

Also Published As

Publication number Publication date
US12492248B2 (en) 2025-12-09
MY208649A (en) 2025-05-22
US20220177564A1 (en) 2022-06-09
TW202136302A (zh) 2021-10-01
US20220177566A1 (en) 2022-06-09
KR102984686B1 (ko) 2026-07-01
EP4072674A1 (en) 2022-10-19
US20220177565A1 (en) 2022-06-09
CA3163910A1 (en) 2021-06-17
MX2022007035A (es) 2022-06-23
JP2023504914A (ja) 2023-02-07
US20260152549A1 (en) 2026-06-04
US20210188965A1 (en) 2021-06-24
JP7641968B2 (ja) 2025-03-07
CN114980974A (zh) 2022-08-30
KR20220123237A (ko) 2022-09-06
BR112022010223A2 (pt) 2022-09-06
WO2021116182A1 (en) 2021-06-17
TW202530257A (zh) 2025-08-01
AU2020400938A1 (en) 2022-07-28
US11840566B2 (en) 2023-12-12
IL293548A (en) 2022-08-01
US12384840B2 (en) 2025-08-12
TWI861302B (zh) 2024-11-11
JP2025081540A (ja) 2025-05-27

Similar Documents

Publication Publication Date Title
AR120698A1 (es) Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
CO2022008576A2 (es) Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα y ox40l
MX2022007035A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
CO2022009239A2 (es) Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα e il-23
CO2023002989A2 (es) Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y ox40l
MX2020008336A (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
CO2019009432A2 (es) Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap.
EA202091976A1 (ru) Вариабельные домены антител, нацеленные на cd33, и их применение
CO2019001367A2 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
MX387295B (es) Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.
BR112018074978A2 (pt) anticorpos para alfa-sinucleína e usos dos mesmos
BR112016030686A2 (pt) anticorpos anti tau humanizados
PE20150023A1 (es) Proteinas de union a antigeno st2
UY36536A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
EA201990822A1 (ru) Иммуномодулирующие слитые белки
CL2021002792A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
CL2021000849A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos (divisional de la solicitud no. 201900999)
MX2021004454A (es) Anticuerpos anti-sinucleina.
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
EA202090838A1 (ru) Иммуномодулирующие слитые белки
AU2017261305A8 (en) DNA monoclonal antibodies targeting influenza virus
EA201692495A8 (ru) Биспецифические антитела к il4-il13